 |
|
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2024;30(3):345-359. Published online 2024 Mar 12 DOI: https://doi.org/10.3350/cmh.2023.0553
|
|
Citations to this article as recorded by
 The potential of lenvatinib in breast cancer therapy
Yuefeng Shang, Tong Liu, Wenjing Wang
Medical Oncology.2024;[Epub] CrossRef Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity
Xiaoyi Zhang, Yachuan Tao, Zhongli Xu, Biao Jiang, Xiaobao Yang, Taomin Huang, Wenfu Tan
Biochemical Pharmacology.2024; 230: 116542. CrossRef Second-line systemic therapy after atezolizumab plus bevacizumab: Is it time to boldly go beyond the known?
Edoardo G. Giannini
Digestive and Liver Disease.2024; 56(12): 2077. CrossRef Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clinical and Molecular Hepatology.2024; 30(4): 1005. CrossRef
|